Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 14th Preview)
-
Regulatory reshuffle at the FDA
Marty Makary resigned as U.S. FDA commissioner, with Kyle Diamantas stepping in as acting commissioner. The leadership change follows a period of internal turnover and industry concern about the predictability of review timelines and guidance, according to multiple reports. For biotech, the immediate impact is uncertainty around how the agency will manage ongoing drug-development reforms, including expedited pathways and AI-adjacent review efforts. With senior drug-review roles operating in an “acting” capacity subject to time limits, observers expect additional personnel movement. The transition raises the risk of operational disruption during a window when sponsors are already coordinating pivotal trial planning and submission timelines around FDA expectations.
-
Targeted protein degradation deal and commercialization of vepdegestrant
Rigel Pharmaceuticals secured a global licensing agreement for vepdegestrant (marketed as Veppanu) after Pfizer and Arvinas reduced their exposure to the estrogen-receptor bifunctional degrader. The arrangement follows U.S. FDA approval earlier in the month, making Veppanu the first bifunctional degrader to reach that milestone. The deal structure shifts commercialization and future milestone dependence to Rigel, while Pfizer and Arvinas recouped value through the out-licensing. Industry follows vepdegestrant closely as the category’s first U.S. test of whether bifunctional degradation can deliver clear differentiation versus established endocrine standards. For sponsors, the transaction underscores the commercial math driving targeted-degradation partnerships—especially when late-stage results don’t clearly outperform existing options.
-
Major pharma-to-pharma collaboration for early oncology and immunology programs
Bristol Myers Squibb and Hengrui Pharma expanded global drug discovery with a collaboration covering 13 early-stage programs across oncology, hematology, and immunology. The pact is valued at up to $15.2 billion, including $600 million upfront and milestone-linked payments through development and commercialization. Hengrui will oversee early clinical development to accelerate proof-of-concept generation, while BMS retains exclusive worldwide rights to Hengrui-originated candidates outside Hengrui’s China/Hong Kong/Macau territory. The companies also plan to jointly discover and develop a subset of assets. The agreement signals renewed appetite for pipeline restocking through China-linked innovation and platform-driven early development, with a structure designed to convert faster early data into global decision points.
-
FDA accelerated approval for sonrotoclax in mantle cell lymphoma
Beone Medicines’ sonrotoclax (Beqalzi) gained U.S. FDA accelerated approval for relapsed or refractory mantle cell lymphoma after treatment with a BTK inhibitor. The approval marks the first BCL2-targeting therapy for this indication in the U.S., and Beone pointed to potential combination positioning with Brukinsa (zanubrutinib). The move brings another “BCL2 plus BTK” sequencing question into clinical practice, as clinicians weigh efficacy, durability, and tolerability in heavily pretreated patients. For Beone and category competitors, accelerated approval is a near-term revenue and trial catalyst—while confirmatory study expectations will shape longer-term value.
-
Obesity drug maintenance strategy: switching from injectables to oral therapy
New clinical data presented at ECO 2026 and published in Nature Medicine suggest that weight loss achieved on injectable obesity therapies can be maintained by transitioning to oral treatment. The findings include evidence for sustained weight reduction when moving to daily oral orforglipron (ATTAIN-MAINTAIN), positioning oral “maintenance” as a strategy to reduce reliance on injectables long-term. Separately, other ECO-released results point to continuing maximum-dose tirzepatide as another maintenance approach, underscoring that trial design choices—dose continuity versus switch—may drive different durability profiles. For payers and providers, these findings add practical options to the obesity care pathway: tapering away from injections without losing the weight-loss plateau.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.